Category: News

Post

SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018

JERSEY CITY, N.J. , May 24, 2018 /PRNewswire/ —  SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced three poster presentations at American Society for Microbiology (ASM) Microbe 2018, READ FULL TEXT

Post

Melinta Therapeutics Announces Pricing of Public Offering of Common Stock

NEW HAVEN, Conn. , May 23, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the pricing of an underwritten public offering of 22,000,000 READ FULL TEXT

Post

SCYNEXIS to Participate in a Panel at the 2018 BIO International Convention

JERSEY CITY, N.J. , May 23, 2018 /PRNewswire/ —  SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that Marco Taglietti , M.D., President and Chief Executive Officer of SCYNEXIS , will READ FULL TEXT

Post

Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidara’s Rezafungin for the Treatment of Invasive Fungal Infections

Four accepted presentations include a late-breaker featuring Phase 2 STRIVE trial data and three posters describing the activity of rezafungin against fungal pathogens SAN DIEGO–(BUSINESS WIRE)–May 23, 2018– Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present four posters highlighting data from preclinical studies and a...

Post

Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity

Data Presented During “New Insights in Acute Pulmonary Infections” Oral Session at American Thoracic Society 2018 International Conference BOSTON, May 22, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today presented a new analysis of the Phase 3 OPTIC...

Post

Melinta Therapeutics Announces Proposed Offering of Common Stock

NEW HAVEN, Conn. , May 21, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that it has commenced an underwritten public offering of READ FULL TEXT

Post

Cidara Therapeutics and Rutgers University Awarded $5.5 Million Grant from NIH to Support Development of Novel Immunotherapy Agents Targeting Multi-drug Resistant Gram-negative Bacterial Infections

New Partnership to Jointly Conduct Preclinical Development of Cidara’s Cloudbreak Antibody-Drug Conjugates SAN DIEGO–(BUSINESS WIRE)–May 21, 2018– Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it and Rutgers University have been awarded a five-year, $5.5 million partnership grant from the U.S. National Institute of Allergy and Infectious...

Post

Cidara Therapeutics Announces Offering of Common Stock and Warrants

SAN DIEGO, May 21, 2018 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has entered into a securities purchase agreement with certain investors providing for the purchase and sale, in a registered direct offering, of up to an aggregate of $120.0 million of its...